Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

ReCode Therapeutics to Present at September Investor Conferences

September 07, 2023 at 08:00 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

ReCode Therapeutics, a clinical-stage company powering the next wave of genetic medicines, today announced that Company management will participate in the following upcoming investor conferences in September 2023:

Morgan Stanley Global Healthcare Conference:

Format: Company Presentation

Date: September 12, 2023

Time: 12:55 p.m. ET

Presenter: David J. Lockhart, Ph.D., President & Chief Scientific Officer of ReCode Therapeutics

Location: New York, NY

Jefferies Cell & Genetic Medicine Summit

Format: Company Presentation

Date: September 26, 2023

Time: 10:30 a.m. ET

Presenter: David J. Lockhart, Ph.D., President & Chief Scientific Officer of ReCode Therapeutics

Location: New York, NY

BMO Biopharma Spotlight Series: Latest Advances in Genome/Epigenome Editing

Format: Panel Discussion - Novel Approaches in Gene Editing and Delivery

Date: September 26, 2023

Time: 2:30 p.m. ET

Presenter: Shehnaaz Suliman, M.D., M.B.A., M.Phil., Chief Executive Officer of ReCode Therapeutics

Location: Virtual

About ReCode Therapeutics

ReCode Therapeutics is a clinical-stage company powering the next wave of genetic medicines. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver. The SORT LNP platform is the foundation for ReCode’s pipeline of disease-modifying mRNA and gene correction therapeutics. ReCode’s lead programs are focused on primary ciliary dyskinesia and cystic fibrosis. ReCode is leveraging its SORT LNP platform and nucleic acid technologies to expand its pipeline with therapeutics that use mRNA-mediated replacement and gene correction in target organs with precision targeting of disease-relevant cells. In 2022, ReCode was named among Fierce Biotech’s “Fierce 15” as one of the most promising early-stage biotechnology companies in the industry and was described by Nature as one of the “Seven Technologies to Watch in 2022” for its SORT LNP platform. For more information, visit www.recodetx.com and follow us on LinkedIn.